Drug recall · January 4, 2023
Ganciclovir for Injection recall
Why: Labeling: Label mix-up - one vial was mislabeled as Cladribine Injection 10mg/mL inside a 10-count carton of Ganciclovir 500 mg.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE GmbH, Germany, Distributed by Hikma Berkeley Heights, NJ 07922, NDC 0143-9299-01
- Lots / codes
Lot#: BQ0006, Exp 08/2023
- Quantity
- 13,760 vials
- Company
- Hikma Pharmaceuticals USA Inc., Cherry Hill, NJ
- Distribution
- USA Nationwide
- Initiated
- December 16, 2022 · Voluntary: Firm initiated
- Classified
- December 27, 2022
- Reported
- January 4, 2023
- Ended
- December 6, 2023
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ganciclovir
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.